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ABSTRACT The amiloride-sensitive epithelial sodium
channel (ENaC) is a heteromultimer of three homologous
subunits (a-, b-, and g-subunits). To study the role of the
b-subunit in vivo, we analyzed mice in which the bENaC gene
locus was disrupted. These mice showed low levels of bENaC
mRNA expression in kidney ('1%), lung ('1%), and colon
('4%). In homozygous mutant bENaC mice, no bENaC
protein could be detected with immunofluorescent staining.
At birth, there was a small delay in lung-liquid clearance that
paralleled diminished amiloride-sensitive Na1 absorption in
tracheal explants. With normal salt intake, these mice showed
a normal growth rate. However, in vivo, adult bENaC mym
mice exhibited a significantly reduced ENaC activity in colon
and elevated plasma aldosterone levels, suggesting hypovole-
mia and pseudohypoaldosteronism type 1. This phenotype was
clinically silent, as bENaC mym mice showed no weight loss,
normal plasma Na1 and K1 concentrations, normal blood
pressure, and a compensated metabolic acidosis. On low-salt
diets, bENaC-mutant mice developed clinical symptoms of an
acute pseudohypoaldosteronism type 1 (weight loss, hyperka-
lemia, and decreased blood pressure), indicating that bENaC
is required for Na1 conservation during salt deprivation.
Regulation of sodium reabsorption in the kidney is essential
for maintaining sodium balance, extracellular-f luid volume,
and blood pressure. Principal cells that line the distal part of
the renal tubule (in particular, the cortical collecting duct) are
targets for aldosterone action, which modulates Na1 reabsorp-
tion. These epithelial cells promote transepithelial Na1 trans-
port by the amiloride-sensitive epithelial sodium channel
(ENaC), located at the apical membrane, facing the lumen,
and by the Na1,K1-ATPase, located at the basolateral mem-
brane. ENaC constitutes a limiting step in sodium reabsorption
(1). The channel is a heterotetrameric protein made of three
homologous subunits (a-, b-, and gENaC; refs. 2–4). When
expressed in Xenopus oocytes, aENaC alone is sufficient to
confer a small amiloride-sensitive sodium current ('50 nA;
ref. 5), but b- and g-subunits are required in addition for
maximal channel activity in vitro (10–20 mA) (2).
The importance of ENaC in sodium homeostasis has been
underlined by the identification of ENaC subunit mutations
that result in Liddle’s syndrome and the autosomal recessive
form of pseudohypoaldosteronism type 1 (PHA-1). When
expressed in Xenopus oocytes, Liddle mutations enhance the
amiloride-sensitive sodium current by increasing the number
and open probability of channels at the cell surface (6–9).
PHA-1 is a salt-wasting syndrome associated with metabolic
acidosis, hyperkalemia, and hyperaldosteronism (10). ENaC
mutations causing PHA-1 have been identified in all three
ENaC subunits (a-, b-, and gENaC; refs. 11 and 12). In the
Xenopus oocyte system, Na1 absorption by mutant ENaC
variants is reduced, compared with wild-type ENaC, but not
abolished (13).
In vitro, coexpression of b- and gENaC subunits in Xenopus
oocytes does not confer channel activity at the cell surface,
indicating that the aENaC subunit might have a specific and
critical role in trafficking the heteromultimeric protein to the
plasma membrane (2, 6). Accordingly, inactivation of the
aENaC gene locus in mice identified the importance of this
subunit in forming functional channels in vivo (14). aENaC
knockout mice died soon after birth with liquid-filled lungs,
underscoring the importance for amiloride-sensitive Na1
transport to clear lung liquid at birth (14). The inactivation of
the gENaC subunit resulted in a severe PHA-1 phenotype and
early death (30–36 h after birth) caused by metabolic and
electrolyte disturbances (15).
The role of the bENaC subunit in vivo is not yet established.
Previous studies showed that, for each subunit, both the
expression pattern and the regulation in lung, kidney, and
colon differ (16–18). ENaC subunits have unique patterns of
distribution within different regions of the lung (17). Thus,
complete or partial inactivation of the bENaC gene locus may
lead to a different phenotype than the one observed for the a-
or gENaC knockout mice. When coexpressed in Xenopus
oocytes, a- and gENaC subunits alone produce an amiloride-
sensitive sodium current whose amplitude is 5% of the activity
of all three subunits in vitro (2). It is not clear whether this
reduced level of ENaC activity is sufficient to maintain Na1
balance in vivo.
In the course of generating a mouse model for Liddle’s
syndrome by the insertion of a stop codon (corresponding to
residue R566 in human bENaC) and the selection marker
neomycin, we obtained mice with a disruption of the bENaC
gene locus. In mice homozygous for the bENaC mutation
(bENaC mym mice), bENaC RNA transcript levels were very
low (,4%). bENaC protein was not detectable by immuno-
fluorescence histochemistry in lung and kidney. Under normal
conditions, this disruption leads to a mild PHA-1 phenotype
and no detectable clinical consequences, but under conditions
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked ‘‘advertisement’’ in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org.
Abbreviations: DPDamil, amiloride-sensitive potential difference; En,
embryonic day n; ENaC, amiloride-sensitive epithelial sodium channel;
PD, potential difference; PHA-1, pseudohypoaldosteronism type 1.
‡P.B., Q.W., and S.A.E. contributed equally to this work.
††To whom reprint requests should be addressed. e-mail: bernard.
rossier@ipharm.unil.ch and ehummler@pop-server.unil.ch.
1732
of low salt intake, the disruption leads to a severe PHA-1
phenotype.
METHODS
Disruption of the bENaC Gene Locus. Genomic fragments
of bENaC were isolated from a 129ySv mouse genomic library
(Stratagene). A 6.8-kb HindIII fragment encompassing the
exon encoding the C terminus was cloned into pBluescript II
KS(2) (Stratagene). A mutation (R566Stop) followed by a
KpnI restriction site was introduced by site-directed mutagen-
esis. This plasmid (pBS6.8HindIIImstop) was used for gener-
ating the targeting vector (pHR-BEM). The PGK-neo-poly(A)
cassette flanked by two loxP sites was inserted in the KpnI site
(Fig. 1A). A HSV-Tk-poly(A) cassette was inserted towards
the 59 end for negative selection. pHR-BEM was linearized at
the unique ClaI site and electroporated into HM-1 ES cells
(14). Correctly targeted clones were expanded and injected
into C57BLy6J blastocysts (19). Male chimeras were bred to
C57BLy6J females. Heterozygotes (F1) were interbred to
obtain mice homozygous for the bENaC mutation (F2 gener-
ation).
Genotyping. Genomic DNA from embryonic stem cell
clones and from mouse tails was prepared as described (20).
Southern blot analysis was performed on DNA digested with
HincII according to standard procedures by using probe A
(Fig. 1B). PCR analyses were performed on 100 ng of DNA (32
cycles of 1 min at 94°C, 1 min at 56°C, and 1 min at 72°C). The
primers were PLS (59-CTTCCAAGAGTTCAACTACCG-39;
position is 11,488 to 11,509; 39 of the translation start site),
PLAS (59-TCTACCAGCTCAGCCACAGTG-39; position is
11,722 to 11,742; 39 of the translation start site; indicated
primer positions correspond to the rat bENaC cDNA se-
quence; ref. 2), and Pneo (59-CTGCTATTGGCCGCTGC-
CCCA-39; position is 1317 to 1337; 39 of the translation start
site of the neomycin-resistance gene).
Northern Blot Analysis. Total RNA from colon, kidney,
lung, and liver was isolated; 15 mg was run on a 0.8% glyoxal
agarose gel and blotted to nylon membranes, according to
standard procedures. The membranes were hybridized with
random primed 32P-labeled probes for rat a-, b-, and gENaC
subunits (2, 5). For quantification of RNA transcripts, loading
was normalized by hybridization with a PCR-amplified cDNA
probe for mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene (14). For each group, RNA from four inde-
pendent animals kept on moderately low-salt diets (1 gykg
Na1; diet 212; Usine Alimentation Rationelle, Epinay-sur-
Orge, France) was analyzed.
Immunocytochemical Analysis and Preparation of Tissues.
Kidney and lung from bENaC 1y1 and mym animals were
fixed and frozen as described (21). The following two anti-
bodies against bENaC were used: a rabbit antibody against the
C terminus of rat bENaC (22) and an affinity-purified guinea
pig antibody against the ectodomain of rabbit bENaC (amino
acids 244–371). Immunoblots were prepared from a fraction
enriched for plasma membranes of Xenopus oocytes coexpress-
ing recombinant a-, b-, and gENaC and stained with this
antibody, and a single 95-kDa band appeared, corresponding
to the size of glycosylated rat bENaC. Immunofluorescent
staining was performed on cryostat sections (5 mm) essentially
as described (22). The anti-bENaC guinea pig antibody and the
rabbit antibody were diluted to 1:300 and 1:500, respectively.
The fluorescein isothiocyanate-conjugated secondary antibod-
ies (Jackson ImmunoResearch) were diluted to 1:200. Sections
were viewed with a Leitz Aristoplan microscope, and images
were recorded on film, digitized, and processed with PHOTO-
SHOP software, version 3.0 (Adobe Systems, Mountain
View, CA).
Lung-Liquid Clearance. To investigate the capacity of the
distal lung (terminal bronchioles and alveoli) to absorb liquid,
distal-lung explants from embryonic-day-16 (E16) to E18
fetuses were cultured on Transwell collagen-coated mem-
branes in F12yDMEM for 48 h to form liquid-filled multicystic
structures. Explants were photographed; 8-(4-chloro-
phenylthio)-cAMP (1025 M) was added to the culture medium,
and explants were rephotographed 24 h later. The change in
the number of inflated cysts after the addition of cAMP was
used as an index of cAMP-sensitive liquid absorption, which
has been shown to be mediated by amiloride-sensitive Na1
absorption (23). Whole-lung water content of fetal or newborn
pups was measured as described (14).
Explant Culture and Bioelectric Measurements. Experi-
ments were performed on tracheal explants from newborn
animals and on freshly excised tracheal epithelia from adult
animals (14). The activity of the epithelial sodium channel in
the distal part of the rectum was measured in vivo as the
amiloride-sensitive rectal potential difference (DPDamil; Q.W.,
E.H., H. Brunner, B.R., J.-D. Horisberger, and M.B., unpub-
FIG. 1. Gene targeting strategy for the disruption of the mouse
bENaC gene locus. (A) Structure of the wild-type bENaC gene, the
targeting vector, and the predicted targeted locus. The ‘‘R566Stop’’
mutation is indicated (asterisk). Expected fragment sizes of the
wild-type and mutated bENaC allele after digestion with HincII and
hybridization with probe A are indicated. H2 5 HincII; H3 5 HindIII;
K1 5 KpnI. The precise exon–intron structure has not been deter-
mined. Identified exons are indicated (shaded box). (B) Southern blot
analysis of offspring from the breeding of chimeras. Tail DNA was
digested with HincII and hybridized with a 59 f lanking probe (probe
A). The bENaC genotype is indicated above each lane. Expected
fragment sizes of wild-type (5-kb) and mutant (7-kb) allele are
indicated. (C) Northern blot analysis of bENaC RNA transcripts from
bENaC 1y1, my1, and mym mice kept on low-salt diets (1 gykg Na1).
Total RNA (15 mg) from colon, kidney, and lung of each four
independent animals was hybridized with bENaC-specific 32P-labeled
probes.
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lished work). In mice homozygous for the bENaC mutation
and in wild-type mice, DPDamil was determined between 4:00
and 6:00 p.m. (the light cycle was from 7:00 a.m. to 7:00 p.m.).
Mice were fed normal diets (3 gykg Na1; diet A03) or low-salt
diets (0.1 gykg Na1; diet 212; Ucine Alimentation Rationelle
Epinay-sur-Orge) for 5 days before DPDamil was measured.
Analytical Procedures and Blood Pressure Measurements.
Adult mice (3–5 months old; bENaC 1y1, my1, and mym)
were fed normal diets (3 gykg Na1) or low-salt diets (0.1 gykg
Na1) for 5–10 days before samples were collected. Urinary
Na1 and K1 excretions were normalized to creatinine con-
centrations. Blood values were determined from arterial blood
taken from the carotid artery after blood pressure was mea-
sured. Plasma aldosterone levels were determined by 125I RIA
(Coat-A-Count Aldosterone kit, Diagnostic Products, Los
Angeles). All assays were run in duplicate. Blood pressure was
measured in adult mice (3–5 months old) by carotid catheter-
ization; 4 h after surgery, mean blood pressure from resting
mice was recorded over 12 min with a computerized data-
acquisition system (24).
Body Weight. bENaC mym and 1y1 mice fed with normal
diets (3 gykg Na1) were weighed at the same time of day for
6 consecutive days. The body weight (at day 6) was determined
as the reference weight. Then, mice were fed the low-salt diet
(0.1 gykg Na1), and their weights were monitored over 8 more
days (days 6–14).
Statistical Analysis. Data are presented as the means 6
SEM. Statistical significance was assessed by using unpaired t
test. P , 0.05 was considered the minimum level of signifi-
cance.
RESULTS
Disruption of the bENaC Gene Locus in Mice. A replace-
ment vector was used to mutate the bENaC gene locus (Fig.
1A). Heterozygous mutant embryonic stem cell clones and
mice (my1) were identified by the presence of a 7-kb band
(Fig. 1B). bENaC my1 mice were interbred to generate
homozygous mutant mice (bENaC mym). Analysis of a total
of 385 mice showed no significant deviation from the expected
Mendelian distribution of genotypes (29% bENaC 1y1, 46%
my1, and 25% mym). bENaC my1 and mym mice were
indistinguishable from 1y1 mice in appearance, growth rate,
and fertility (data not shown). In bENaC my1 mice, Northern
blot analysis showed reduced expression of the 2.5-kb bENaC
mRNA in colon (69 6 16%; P 5 0.17), kidney (64 6 4%; P ,
0.01), and lung (48 6 5%; P , 0.05; Fig. 1C) compared with
bENaC 1y1 mice. In bENaC mym mice, low levels of a 4.5-kb
RNA transcript were detected in colon (4 6 2%), kidney (1 6
1%), and lung (1 6 1% of wild-type RNA transcript; Fig. 1C).
In bENaC 1y1, my1, and mym mice, no significant differ-
ence in aENaC mRNA was found in these organs (data not
shown). However, in bENaC mym mice, an up-regulation of
the gENaC mRNA was observed in colon (.23 increased;
280 6 67%; P , 0.05) but not in kidney and lung (data not
shown).
Immunolocalization of bENaC. An affinity-purified anti-
body to the ectodomain of the subunit was used to detect
expression of both wild-type protein and the mutant bENaC
that lacks part of the C terminus. In wild-type mice, both the
C-terminal antibody (Fig. 2 A and B) and the ectodomain
antibody (Fig. 2 C and D) showed localization to late distal
tubules and to principal cells of collecting tubules, which
comprise most of the collecting tubule epithelium and are
known to be the site of ENaC-mediated Na1 transport.
Staining was present throughout the cytoplasm. Specific im-
munofluorescence staining at the luminal pole, distinct from
the cytoplasmic signal, could be resolved only when animals
were kept on low-salt diets (data not shown). No specific
staining was seen in other nephron segments. In contrast to
principal cell immunoreactivity, intercalated cells, which are
involved in acidybase balance, were unstained (Fig. 2 A–D). In
lung of wild-type animals, immunofluorescence staining by the
ectodomain antibody was confined to epithelial cells lining the
conducting portions of the respiratory tract, including bronchi,
bronchioles, and terminal bronchioles (Fig. 2 G and H). In
contrast to the immunolocalization of bENaC in wild-type
tissues (Figs. 2 C and G), no specific staining with the
ectodomain antibody was observed in kidney (Fig. 2 E and F)
or lung (Fig. 2 I and J) of bENaC mym mice.
Role of bENaC in Lung. We assessed perinatal lung-liquid
clearance with whole-lung wetydry weight ratios from E19
fetuses and newborn mice (4, 12, and 24 h after birth; Fig. 3A).
bENaC mym mice were able to clear fetal liquid (determined
by water content in the lungs) from the air spaces at 12 h of age,
when, normally, the lung has cleared most of the residual fetal
FIG. 2. Immunolocalization of bENaC protein in kidney (A–F) and
lung (G–J) of bENaC 1y1 and bENaC mym mice by using C-terminal
antibody (A and B) and ectodomain antibody (C–J). (Left) Immuno-
fluorescence. (Right) Corresponding Normarski images. In cortical
collecting ducts (CD) from wild-type mice (A–D), immunofluores-
cence was present in the cytoplasm of principal cells, whereas inter-
calated cells (arrowheads) were unreactive. Cells of proximal convo-
luted tubules and glomeruli (G) were unstained. In contrast, no
staining was detected in kidney of bENaC mym mice (E and F). In lung
of wild-type mice (G and H), signal was present in bronchioles (B) and
terminal bronchioles (TB). No specific immunostaining was present in
lung from the bENaC mym mice (I and J). The faint, nonspecific
f luorescence in I is nonepithelial and associated with basement
membrane. (Scale bar 5 25 mm.)
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liquid. By contrast, at 4 h after birth, lung-liquid clearance was
retarded minimally, but significantly, in bENaC mym mice
compared with bENaC wild-type mice (wetydry ratio; 5.83 6
0.10 in bENaC mym mice vs. 5.57 6 0.05 in bENaC 1y1 mice;
n 5 52; P , 0.05). In cultured distal-lung explants from
E16–E18 fetuses, liquid absorption after exposure to CPT-
cAMP in bENaC mym mice was diminished significantly in
comparison with bENaC 1y1 explants (P , 0.01; Fig. 3B).
Amiloride-sensitive short-circuit current in freshly excised
newborn (Fig. 3C) and adult (Fig. 3D) trachea was diminished
significantly in bENaC mym compared with wild-type mice.
Amiloride-sensitive Na1 transport in explants from neonate
bENaC my1 mice was not significantly different from wild-
type explants (data not shown). Despite a 6-fold reduction in
ENaC-mediated transport in trachea, neonate bENaC mym
mice were still able to clear their lungs of liquid. This result is
consistent with findings in gENaC knockout (15) and aENaC
transgenic knockout mice (25), indicating that relatively low
amiloride-sensitive Na1 conductance clears lungs of liquid at
birth and keeps them dry after birth.
Role of bENaC in Kidney and Colon: Normal-Salt Diet. In
colon, bENaC mym mice exhibited a significant 3-fold lower
ENaC-mediated transport measured by DPDamil than bENaC
1y1 mice (Fig. 4A; P , 0.01). In response to normal-salt diets
(3 gykg Na1), bENaC mym mice excreted significantly more
Na1 and K1 in urine than wild-type mice (Fig. 4B; for each
group, n 5 17; P , 0.05), but the [Na1]y[K1] ratio did not
differ significantly ([Na1]y[K1] ratios were 1.13 6 0.14 for
bENaC mym vs. 0.96 6 0.11 for bENaC 1y1). This result
might be explained by an enhanced food intake, thus com-
pensating for salt wasting. bENaC mym mice exhibited normal
values of serum [Na1] [151.7 6 1.0 mM in bENaC mym (n 5
8) vs. 148.7 6 0.8 mM in bENaC 1y1 mice (n 5 7)], of serum
[K1] [4.49 6 0.24 mM in bENaC mym (n 5 8) vs. 4.29 6 0.09
mM in bENaC 1y1 mice (n 5 7)], and of blood pH (Fig. 4C).
However, a significant decrease in [HCO3
2] (Fig. 4C) and lower
PCO2 [32.0 6 1.5 mmHg in bENaC mym (n 5 7) vs. 39.6 6
1.1 mmHg in bENaC 1y1 (n 5 5); 1 mmHg 5 133 Pa; P ,
0.01] indicate a compensated metabolic acidosis. Furthermore,
we observed a significant 1.8-fold higher plasma aldosterone
level in bENaC mym mice (Fig. 4D). Thus, with normal-salt
diets, bENaC mym mice exhibit a compensated PHA-1 phe-
notype.
Low-Salt Diet. During feeding with low-salt diets (0.1 gykg
Na1), bENaC mym mice continuously lost body weight. Sig-
nificant differences between bENaC mym and 1y1 mice were
FIG. 3. Liquid absorption in lung explants. (A) Mean whole-lung water content (wetydry weight ratio) in bENaC mym mice (closed triangles)
and bENaC 1y1 mice (open circles). p, P , 0.05. (B) Liquid absorptive capacity measured as percentage of cysts that remained inflated after
stimulation by 1025 M cAMP in explants from bENaC mym (black bars) and 1y1 mice (white bars) at E16–E18. (C and D) Short-circuit currents
(DIsc) in tracheal explants from newborn (C) and adult (D) mice. bENaC 1y1 (white bars); bENaC mym (black bars). Treatment with 1024 M
amiloride (amil), 3 3 1024 M terbutaline (terb), and 1024 M UTP, all of which stimulate Cl2 secretion, confirms the viability of the bENaC mym
explants.
FIG. 4. Physiological measurement in adult bENaC 1y1 (white bars) and mym (dark bars) mice on normal-salt (3 gykg Na1) diets. (A) In vivo
measurements of DPDamil (bENaC 1y1, n 5 16; bENaC mym, n 5 17). pp, P , 0.01. (B) Relative values of urinary Na1 and K1 normalized with
creatinine (Creat; for each group, n 5 17). p, P , 0.05; pp, P , 0.01. (C) Arterial blood pH and HCO3
2 (bENaC 1y1, n 5 5; bENaC mym, n 5
7). p, P , 0.05. (D) Plasma aldosterone concentrations (nM; for each group, n 5 7). p, P , 0.05.
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evident by the second day of treatment (Fig. 5; P , 0.01). After
8 days of the low-salt diet (day 14; Fig. 5), bENaC mym mice
had lost '20% (20.3 6 5.9%) of their initial weight, whereas
the controls had lost only '7% (6.3 6 3.6%; P , 0.01). In
blood plasma, [K1] was elevated (Fig. 6A; P , 0.01), whereas
[Na1] was in the normal range [mym 152.1 6 1.5 mM in
bENaC mym mice (n 5 7) vs. 151.5 6 2.1 mM in bENaC 1y1
mice (n 5 7)]. In urine, excretion of Na1 and K1 did not differ
significantly between both groups fed with low-salt diets, even
though [Na1]y[creatinine] in bENaC mym mice was increased
3-fold compared with the controls (Fig. 6B). Aldosterone was
stimulated in both groups on low-salt diets (2.63 in bENaC
mym mice and 2.83 in bENaC 1y1 mice; see Fig. 4C) but was
increased 1.63 in bENaC mym mice compared with their
controls (Fig. 6C; P , 0.01). In vivo measurements of DPDamil
in distal colon showed that bENaC mym mice, when kept on
low-salt diets, are able to increase their sodium transport (Fig.
4A), but ENaC activity is reduced in comparison with bENaC
1y1 mice (Fig. 6D; P , 0.01). The consequences of low-salt
diet (0.1 gykg Na1) on mean blood pressure were also deter-
mined (Fig. 6E). In bENaC mym mice on low-salt diets, mean
blood pressure was reduced in comparison to mym mice kept
on normal-salt diets (P , 0.05; Fig. 6E). In controls, mean
blood pressure did not change with low-salt diets, indicating
that normal bENaC expression is required for Na1 conserva-
tion during salt deprivation.
DISCUSSION
Disruption of the bENaC Gene Locus. Our strategy resulted
in (i) large decreases of bENaC RNA transcripts in kidney,
colon, and lung, (ii) the absence of bENaC protein expression,
and (iii) reduced ENaC activity as indicated by several phys-
iological parameters. These findings were unexpected, because
the insertion of a stop codon, which is analogous to the
mutation found in patients with Liddle’s syndrome, should not
affect RNA levels and instead lead to increased ENaC density
and activity (6, 9, 26). We suggest that the insertion of an
additional selection marker [in this study, the insertion of the
neomycin-resistance gene (neo) into 39 untranslated sequenc-
es] resulted in destabilization andyor degradation of the
bENaC mRNA transcripts (27). In vivo, the presence of neo
could interfere with the expression of the corresponding gene
locus or down-regulate gene activity (28). For example, inclu-
sion of a neo cassette in an intron interfered with the expres-
sion of the Gbx2 gene (29), presumably because the neo
cassette contained cryptic splice sites (30). Preliminary data
indeed indicated that removing the neo cassette by using the
Cre-loxP-mediated recombination system (Cre-expressing
mice) efficiently restored bENaC expression in bENaC mym
mice (S.P., Q.W., S.E., M.B., F.B., E.H., and B.R., unpublished
data).
Role of bENaC in Vivo. Reduced ENaC activity is still
present in colon and lung of bENaC mym mice. In contrast to
aENaC knockout mice, in which the inactivation of a-subunit
causes a fatal inability to clear lung-liquid, bENaC mym mice
showed only a minor delay in lung-liquid clearance in the first
hours of life (ref. 15; Fig. 3 A–D). Similarly, animals in which
the gENaC subunit was inactivated could still clear lung liquid
at birth. However, they died soon after birth with PHA-1
symptoms like urinary salt wasting and hyperkalemia (15). In
bENaC mym mice, the absorptive capacity could be provided
by channels associated with only a- or gENaC subunits or
those in combination with residual bENaC subunits. There-
fore, ENaC function might be sufficient in the near absence of
FIG. 5. Body-weight measurements in bENaC 1y1 (n 5 12; open
squares) and mym (n 5 8; closed squares) mice. Animals were kept 6
days (days 0–6) on normal-salt diets (3 gykg Na1), which then were
replaced by low-salt diets (0.1 gykg Na1) for 8 more days (days 6–14).
Body weights of each group are indicated as percentage of reference
weight (100% at day 6). Mice were weighed daily at the same time.
FIG. 6. Physiologic measurements in adult bENaC mym (black
bars) and 1y1 (white bars) mice on low-salt diets (0.1 gykg Na1;
A–D). (A) Plasma K1. For each group, n 5 7. pp, P , 0.01. (B) Relative
values of urinary Na1 and K1 normalized with creatinine (Creat). For
bENaC 1y1, n 5 7; for bENaC mym, n 5 6. (C) Plasma aldosterone
levels (nM). For each group, n 5 6. pp, P , 0.01. (D) In vivo
measurements of DPDamil. For bENaC 1y1, n 5 6; for bENaC mym,
n 5 7. pp, P , 0.01. (E) Mean blood-pressure measurements in bENaC
1y1 (n 5 7) and mym (n 5 8) mice on normal-salt diets (NS; 3 gykg
Na1) and low-salt diets (LS; 0.1 gykg Na1). p, P , 0.05.
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bENaC expression to maintain salt and water homeostasis
under normal dietary conditions. Fully active ENaCs, how-
ever, are required to maintain total body water and electrolyte
balance under low-salt dietary conditions. Therefore, bENaC
mym mice present a model for studying the role of the bENaC
subunit in vivo.
Salt Restriction Induces PHA-1 in bENaC mym Mice. The
bENaC mym and the previously described aENaC knockout
transgenic mice present two different types of PHA-1 mouse
models. In aENaC knockout transgenic mice, the transgene is
no longer under aldosterone control and constitutes the lim-
iting subunit for ENaC activity (25). In bENaC mym mice,
increased plasma aldosterone concentrations can still act on
bENaC as well as on aENaC andyor gENAC subunit expres-
sion. Indeed, in these animals, an up-regulation of gENaC
mRNA in colon has been observed. On normal-salt diets,
bENaC mym mice can maintain plasma [Na1], [K1], and blood
pressure in the normal range. However, on low-salt diets,
bENaC mym mice cannot sufficiently adapt to maintain
sodium balance, and they show clinical symptoms of an acute
PHA-1, although Na1 transport was increased in colon. In
humans, PHA-1 is a heterogeneous clinical syndrome ranging
from severe salt loss in infancy to a clinically less severe
syndrome aggravated by salt depletion (11, 31–33). With
respect to these clinical cases described, the bENaC mym mice
present a mouse model which is appropriate to the human
situation.
In the present study, bENaC subunit limits channel function
under conditions like low-salt intake. bENaC mym mice try to
respond to this ‘‘challenge’’ by stimulating the renal–adrenal
axis (elevated plasma aldosterone levels). In these mice,
mutation of the mouse bENaC gene locus could confer salt
resistance. This assumption is of particular interest, because, in
human populations, PHA-1 mutations might be silent; a
PHA-1 phenotype is provoked only by environmental chal-
lenge. Our study emphasizes the importance of all three
subunits in forming functional and aldosterone-regulated
channels in kidney and colon under different dietary Na1
conditions.
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